211 related articles for article (PubMed ID: 25305133)
1. An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes.
Shafie AA; Gupta V; Baabbad R; Hammerby E; Home P
Diabetes Res Clin Pract; 2014 Nov; 106(2):319-27. PubMed ID: 25305133
[TBL] [Abstract][Full Text] [Related]
2. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
3. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
Ray JA; Valentine WJ; Roze S; Nicklasson L; Cobden D; Raskin P; Garber A; Palmer AJ
Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting.
Valentine WJ; Palmer AJ; Lammert M; Nicklasson L; Foos V; Roze S
Curr Med Res Opin; 2005 Dec; 21(12):2063-71. PubMed ID: 16368057
[TBL] [Abstract][Full Text] [Related]
6. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of switching to biphasic insulin aspart from human premix insulin in a US setting.
Palmer JL; Knudsen MS; Aagren M; Thomsen TL
J Med Econ; 2010; 13(2):212-20. PubMed ID: 20350145
[TBL] [Abstract][Full Text] [Related]
8. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes.
Valentine WJ; Pollock RF; Plun-Favreau J; White J
Curr Med Res Opin; 2010 Jun; 26(6):1399-412. PubMed ID: 20387997
[TBL] [Abstract][Full Text] [Related]
10. An analysis of the cost-effectiveness of starting insulin detemir in insulin-naïve people with type 2 diabetes.
Home P; Baik SH; Gálvez GG; Malek R; Nikolajsen A
J Med Econ; 2015 Mar; 18(3):230-40. PubMed ID: 25407031
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
Palmer JL; Beaudet A; White J; Plun-Favreau J; Smith-Palmer J
Adv Ther; 2010 Nov; 27(11):814-27. PubMed ID: 21061114
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes.
Luo Q; Zhou L; Zhou N; Hu M
Front Public Health; 2022; 10():1016937. PubMed ID: 36330105
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
Lim-Abrahan MA; Jain AB; Bebakar WM; Seah D; Soewondo P
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
[TBL] [Abstract][Full Text] [Related]
16. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
17. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
Lezzar A; Ayad F; Dahaoui A; Salah-Mansour A; Berrouiguet AY
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S37-44. PubMed ID: 23958570
[TBL] [Abstract][Full Text] [Related]
18. Criteria influencing the choice of starting insulin regimen in patients with type 2 diabetes in routine clinical practice: baseline data from the Algerian cohort of the A₁chieve study.
Malek R; Arbouche Z; Bachaoui M; Zinai S; Dahaoui A; Senoussaoui S; Salah-Mansour A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S45-9. PubMed ID: 23958572
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
[TBL] [Abstract][Full Text] [Related]
20. Biphasic insulin aspart 30 treatment for people with type 2 diabetes: a budget impact analysis based in Thailand.
Deerochanawong C; Kosachunhanun N; Chotikanokrat P; Permsuwan U
Curr Med Res Opin; 2018 Feb; 34(2):369-375. PubMed ID: 29172837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]